Insider · CIK 0001856369
Christopher Gibson
ceoofficerdirector
Files at PACB (PACIFIC BIOSCIENCES OF CALIFORNIA, INC.), RXRX (RECURSION PHARMACEUTICALS, INC.). First filing Nov 15, 2024, latest Mar 25, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 21
$0 bought, $9.7M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RXRX: RECURSION PHARMACEUTICALS, INC.
RXRXOct 9, 2026 · close 4.36
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | RECURSION PHARMACEUTICALS, INC. | $130k 40,000 shares | -4% | 0% from low-52% from high | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | $138k 40,000 shares | -4% | +8% from low-66% from high | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | $165k 40,000 shares | -4% | +1% from low-64% from high | |
| 15Weak | RECURSION PHARMACEUTICALS, INC. | $179k 40,000 shares | -4% | +14% from low-60% from high | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | $170k 40,000 shares | -4% | +14% from low-60% from high | |
| 32Weak | RECURSION PHARMACEUTICALS, INC. | $180k 40,000 shares | -4% | +11% from low-61% from high | |
| 25Weak | RECURSION PHARMACEUTICALS, INC. | $185k 40,000 shares | -4% | +28% from low-55% from high | |
| 24Weak | RECURSION PHARMACEUTICALS, INC. | $166k 40,000 shares | -4% | +2% from low-63% from high | |
| 17Weak | RECURSION PHARMACEUTICALS, INC. | $208k 40,000 shares | -4% | +26% from low-54% from high | |
| 24Weak | RECURSION PHARMACEUTICALS, INC. | $570k 100,000 shares | -9% | +44% from low-47% from high | |
| 24Weak | RECURSION PHARMACEUTICALS, INC. | $604k 100,000 shares | -9% | +34% from low-51% from high | |
| 23Weak | RECURSION PHARMACEUTICALS, INC. | $476k 100,000 shares | -9% | +17% from low-57% from high | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | $471k 100,000 shares | -9% | +14% from low-58% from high | |
| 31Weak | RECURSION PHARMACEUTICALS, INC. | $484k 100,000 shares | -9% | +22% from low-56% from high | |
| 48Moderate | RECURSION PHARMACEUTICALS, INC. | $3.3M 618,175 shares | -41% | +33% from low-51% from high | |
| 33Weak | RECURSION PHARMACEUTICALS, INC. | $837k 138,574 shares | -11% | - | |
| 18Weak | RECURSION PHARMACEUTICALS, INC. | $259k 40,000 shares | -3% | - | |
| 19Weak | RECURSION PHARMACEUTICALS, INC. | $316k 40,000 shares | -3% | - | |
| 19Weak | RECURSION PHARMACEUTICALS, INC. | $287k 40,000 shares | -5% | - | |
| 19Weak | RECURSION PHARMACEUTICALS, INC. | $286k 40,000 shares | -5% | - | |
| 34Weak | RECURSION PHARMACEUTICALS, INC. | $302k 40,000 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 5, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 20,000 0.01% of outstanding | $142k | Dec 5, 2024 | $813k |
| Dec 4, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 20,000 0.01% of outstanding | $143k | Dec 4, 2024 | $790k |
| Nov 14, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 20,000 0.01% of outstanding | $147k | Nov 14, 2024 | $643k |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 20,000 0.01% of outstanding | $155k | Nov 13, 2024 | $488k |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 946,556 | Mar 25, 2026 |
| Mar 23, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $3.25 | $130k | 906,556 | Mar 25, 2026 |
| Mar 23, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,483,334 | Mar 25, 2026 |
| Mar 9, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 926,556 | Mar 11, 2026 |
| Mar 9, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 906,556 | Mar 11, 2026 |
| Mar 9, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 4,523,334 | Mar 11, 2026 |
| Mar 3, 2026 | PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | AGrant or award Common Stock | +53,913 | $0.00 | $0 | 53,913 | Mar 5, 2026 |
| Mar 3, 2026 | PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | AGrant or award Stock Option (right to buy)derivative | +73,087 | $0.00 | $0 | 73,087 | Mar 5, 2026 |
| Feb 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock10b5-1 | -27,265 | $3.49 | $95k | 906,556 | Feb 19, 2026 |
| Feb 19, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 946,556 | Feb 19, 2026 |
| Feb 19, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $3.46 | $138k | 906,556 | Feb 19, 2026 |
| Feb 19, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,543,334 | Feb 19, 2026 |
| Feb 4, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 953,839 | Feb 6, 2026 |
| Feb 4, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.12 | $165k | 913,839 | Feb 6, 2026 |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock10b5-1 | +30,346 | $0.00 | $0 | 944,185 | Feb 6, 2026 |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock10b5-1 | -10,364 | $3.56 | $37k | 933,821 | Feb 6, 2026 |
| Feb 4, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,583,334 | Feb 6, 2026 |
| Jan 20, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 953,839 | Jan 22, 2026 |
| Jan 20, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.47 | $179k | 913,839 | Jan 22, 2026 |
| Jan 20, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,623,334 | Jan 22, 2026 |
| Jan 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +60,000 | $0.00 | $0 | 973,839 | Jan 7, 2026 |
| Jan 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.25 | $170k | 933,839 | Jan 7, 2026 |
| Jan 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 913,839 | Jan 7, 2026 |
| Jan 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -60,000 | $0.00 | $0 | 4,663,334 | Jan 7, 2026 |
| Dec 19, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 953,839 | Dec 19, 2025 |
| Dec 19, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.50 | $180k | 913,839 | Dec 19, 2025 |
| Dec 19, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,723,334 | Dec 19, 2025 |
| Dec 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +60,000 | $0.00 | $0 | 973,839 | Dec 5, 2025 |
| Dec 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.63 | $185k | 933,839 | Dec 5, 2025 |
| Dec 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 913,839 | Dec 5, 2025 |
| Dec 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -60,000 | $0.00 | $0 | 4,763,334 | Dec 5, 2025 |
| Nov 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock10b5-1 | -40,390 | $4.14 | $167k | 913,839 | Nov 19, 2025 |
| Nov 19, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +40,000 | $0.00 | $0 | 953,839 | Nov 19, 2025 |
| Nov 19, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $4.16 | $166k | 913,839 | Nov 19, 2025 |
| Nov 19, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -40,000 | $0.00 | $0 | 4,823,334 | Nov 19, 2025 |
| Nov 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +60,000 | $0.00 | $0 | 1,014,229 | Nov 6, 2025 |
| Nov 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -40,000 | $5.21 | $208k | 974,229 | Nov 6, 2025 |
| Nov 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 954,229 | Nov 6, 2025 |
| Nov 4, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -60,000 | $0.00 | $0 | 4,863,334 | Nov 6, 2025 |
| Oct 23, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +100,000 | $0.00 | $0 | 1,054,229 | Oct 24, 2025 |
| Oct 23, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $5.70 | $570k | 954,229 | Oct 24, 2025 |
| Oct 23, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -100,000 | $0.00 | $0 | 4,923,334 | Oct 24, 2025 |
| Oct 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +120,000 | $0.00 | $0 | 1,074,229 | Oct 10, 2025 |
| Oct 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $6.04 | $604k | 974,229 | Oct 10, 2025 |
| Oct 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 954,229 | Oct 10, 2025 |
| Oct 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -120,000 | $0.00 | $0 | 5,133,034 | Oct 10, 2025 |
| Sep 25, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +100,000 | $0.00 | $0 | 1,054,229 | Sep 26, 2025 |
| Sep 25, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $4.76 | $476k | 954,229 | Sep 26, 2025 |
| Sep 25, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -0 | $0.00 | $0 | 5,253,034 | Sep 26, 2025 |
| Sep 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +120,000 | $0.00 | $0 | 1,074,229 | Sep 12, 2025 |
| Sep 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $4.71 | $471k | 974,229 | Sep 12, 2025 |
| Sep 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -20,000 | $0.00 | $0 | 954,229 | Sep 12, 2025 |
| Sep 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -120,000 | $0.00 | $0 | 5,253,034 | Sep 12, 2025 |
| Aug 26, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +100,000 | $0.00 | $0 | 1,054,229 | Aug 28, 2025 |
| Aug 26, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -100,000 | $4.84 | $484k | 954,229 | Aug 28, 2025 |
| Aug 26, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -100,000 | $0.00 | $0 | 5,373,034 | Aug 28, 2025 |
| Aug 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -40,390 | $5.64 | $228k | 954,229 | Aug 19, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +423,666 | $0.00 | $0 | 1,504,919 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -500,300 | $5.28 | $2.6M | 1,004,619 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | GGift Class A Common Stock10b5-1 | -10,000 | $0.00 | $0 | 994,619 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stockindirect: by LAHWRAN-3 LLC10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stockindirect: by LAHWRAN-3 LLC10b5-1 | -100,000 | $5.28 | $528k | 0 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stockindirect: by Gibson Family Trust10b5-1 | +17,875 | $0.00 | $0 | 17,875 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stockindirect: by Gibson Family Trust10b5-1 | -17,875 | $5.28 | $94k | 0 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -423,666 | $0.00 | $0 | 5,473,034 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivativeindirect: by LAHWRAN-3 LLC10b5-1 | -100,000 | $0.00 | $0 | 386,000 | Aug 13, 2025 |
| Aug 11, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivativeindirect: by Gibson Family Trust10b5-1 | -17,875 | $0.00 | $0 | 50,000 | Aug 13, 2025 |
| May 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -36,197 | $4.25 | $154k | 1,081,253 | May 19, 2025 |
| Mar 27, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -138,574 | $6.04 | $837k | 1,117,450 | Mar 28, 2025 |
| Mar 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,276,024 | Mar 7, 2025 |
| Mar 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $6.58 | $132k | 1,256,024 | Mar 7, 2025 |
| Mar 6, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,276,024 | Mar 7, 2025 |
| Mar 6, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $6.37 | $127k | 1,256,024 | Mar 7, 2025 |
| Mar 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,916,700 | Mar 7, 2025 |
| Mar 6, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,896,700 | Mar 7, 2025 |
| Feb 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -17,132 | $10.64 | $182k | 1,256,024 | Feb 20, 2025 |
| Feb 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,293,156 | Feb 7, 2025 |
| Feb 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.68 | $154k | 1,273,156 | Feb 7, 2025 |
| Feb 6, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 1,293,156 | Feb 7, 2025 |
| Feb 6, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $8.12 | $162k | 1,273,156 | Feb 7, 2025 |
| Feb 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,956,700 | Feb 7, 2025 |
| Feb 6, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,936,700 | Feb 7, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +525,283 | $0.00 | $0 | 1,261,916 | Feb 5, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +16,809 | $0.00 | $0 | 1,278,725 | Feb 5, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -5,569 | $7.25 | $40k | 1,273,156 | Feb 5, 2025 |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,050,567 | $0.00 | $0 | 1,050,567 | Feb 5, 2025 |
| Jan 8, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Jan 13, 2025 |
| Jan 8, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.31 | $146k | 736,633 | Jan 13, 2025 |
| Jan 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Jan 13, 2025 |
| Jan 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.05 | $141k | 736,633 | Jan 13, 2025 |
| Jan 8, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,996,700 | Jan 13, 2025 |
| Jan 10, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 5,976,700 | Jan 13, 2025 |
| Dec 4, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Dec 6, 2024 |
| Dec 4, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.16 | $143k | 736,633 | Dec 6, 2024 |
| Dec 5, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 756,633 | Dec 6, 2024 |
| Dec 5, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.12 | $142k | 736,633 | Dec 6, 2024 |
| Dec 4, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,036,700 | Dec 6, 2024 |
| Dec 5, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,016,700 | Dec 6, 2024 |
| Nov 15, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -26,023 | $6.18 | $161k | 736,633 | Nov 19, 2024 |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 782,656 | Nov 15, 2024 |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.74 | $155k | 762,656 | Nov 15, 2024 |
| Nov 14, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 782,656 | Nov 15, 2024 |
| Nov 14, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.35 | $147k | 762,656 | Nov 15, 2024 |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,076,700 | Nov 15, 2024 |
| Nov 14, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,056,700 | Nov 15, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.